University of California San Francisco

Laura Van 'T Veer, PhD

Laura Van 'T Veer, PhD
Laura Van 'T Veer, PhD

Professor, Laboratory Medicine

Associate Director Applied Genomics

Address

2340 Sutter Street
San Francisco, CA 94115
United States

Email: [email protected]

Education

Institution Degree Dept or School End Date
University of Leiden, Leiden, Netherlands PhD Medicine, Oncogene Activation and Tumorigenesis 1989
University of Amsterdam, Amsterdam, Netherlands MSc Experimental Oncology 1984
University of Amsterdam, Amsterdam, Netherlands BSc Biology, Molecular Oncology 1980

Awards & Honors

Award Conferred By Date
Luigi Castagnetta Award Progretto Amazzone, Sicily Italy 2024
William McGuire Memorial Lecture Award San Antonio Breast Cancer Symposium 2024
Fellow of the European Academy of Cancer Sciences European Academy of Cancer Sciences 2022
Patient Advocate Hero of Cancer Award Inspire2Live 2020
Giants of Cancer Care OncLive 2020
Luminary Award Precision Medicine World Conference 2020
One of 32 Amazing Women Inventors (living women inventors you should know about) 24/7 Wall Street (https://247wallst.com/) 2018
ECCO Clinical Research Award European CanCer Organization (ECCO) 2017
European Inventor Award (Small-Medium Enterprises) European Patent Office (EPO) 2015
Breast Cancer Research Fund (BCRF-Pink Ribbon US) grant award Breast Cancer Research Fund 2014
Second Prize, European Union Prize for Women Innovators European Union Prize for Women Innovators 2014
AACC Outstanding Speaker Award AACC 2012
Antoni van Leeuwenhoek Outstanding Science Award The Netherlands Cancer Institute 2010
First Annual Harry and Edith Gladstein Award, Indiana University, School of Medicine 2009
Lifetime Achievement Award for Translational Research in Breast Cancer European Society Medical Oncology (ESMO) 2007
Van der Scheuren Award Lecture for European Breast Cancer Research EBCC5 2006
Medal of Honor International Agency for Research on Cancer (IARC) , Lyon, France 2005
Postdoctoral Fellowship The Irvington Institute for Medical Research, New York, USA 1991/1994
Long-term Fellowship NWO The Netherlands Organization for Scientific Research, 's-Gravenhage, The Netherlands 1989/1990

Grants and Funding

  • WISDOM: A platform to optimize subtype-specific screening and prevention | NIH/NCI | 2024-07-01 - 2029-06-30 | Role: Co-Investigator
  • The I SPY 2.2 TRIAL: Evolving to Imaging and Molecular Biomarker Response Directed Adaptive Sequential Treatment to Optimize Breast Cancer Outcomes | NIH/NCI | 2023-07-01 - 2028-06-30 | Role: Project Principal Investigator
  • Comprehensive Cancer Center Support Grant | NIH/NCI | 2018-06-01 - 2028-05-31 | Role: Program Principal Investogator
  • Low-Pass Whole-Genome Sequencing to Improve Breast Cancer Risk Assessment in a Diverse Population | DOD | 2024-04-01 - 2028-03-31 | Role: Principal Investigator
  • The Cancer Cell Map Initiative v2.0 | NCI | 2022-09-14 - 2027-08-31 | Role: Co-Investigator
  • Treatment-induced Changes in Molecular and Pathway Dynamics as Determinants of Non-Response | Breast Cancer Research Foundation | 2014-10-01 - 2026-09-30 | Role: Principal Investigator
  • Strategy for combining circulating tumor DNA (ctDNA) and magnetic resonance imaging (MRI) measures of tumor burden for prediction of response and outcome in neoadjuvant-treated early breast cancer | NIH | 2020-12-03 - 2025-11-30 | Role: Principal Investigator
  • Center for Big Data in Translational Genomics | NIH | 2014-09-29 - 2021-08-31 | Role: Co-Principal Investigator
  • Integrative signaling models to decipher complex cancer phenotypes | NIH | 2012-08-08 - 2017-07-31 | Role: Co-Principal Investigator
  • Leukocyte Biomarkers for Predicting Human Breast Cancer Outcomes | NIH | 2011-09-23 - 2017-07-31 | Role: Co-Principal Investigator
  • SPORE in Breast Cancer | NIH | 1992-09-30 - 2013-11-30 | Role: Principal Investigator

Publications

MOST RECENT PUBLICATIONS FROM A TOTAL OF 10
  1. Risk-Based vs Annual Breast Cancer Screening: The WISDOM Randomized Clinical Trial.
    Esserman LJ, Fiscalini AS, Naeim A, Van't Veer LJ, Kaster A, Scheuner MT, LaCroix AZ, Borowsky AD, Anton-Culver H, Olopade OI, Esserman J, Lancaster R, Madlensky L, Blanco AM, Ross KS, Goodman DL, Tong BS, Hogarth M, Heditsian D, Brain S, Lee V, Blum K, Kim MO, Sabacan LP, Fergus KB, Yau C, Park HL, Parker BA, Kaplan C, Rhoads KF, Eder S, Adduci K, Matthews JB, Wenger NS, Shieh Y, Hiatt RA, Ziv E, Tice JA, Eklund M| | PubMed
  2. Germline Pathogenic Variants Among Women Without a History of Breast Cancer: A Secondary Analysis of the WISDOM Randomized Clinical Trial.
    Fergus KB, Ross KS, Scheuner MT, Blanco AM, Tice JA, Ziv E, Shieh Y, van 't Veer L, Olopade OI, Goodman DL, Tong BS, Harvey H, DeRosa D, Risty L, Silver E, Kaster A, Fiscalini AS, Blum K, Heise R, Sabacan L, Heditsian D, Brain S, Petruse A, Eklund M, Hiatt RA, Borowsky AD, Naeim A, Park HL, LaCroix AZ, Parker BA, Lancaster R, Esserman J, Wenger N, Arasu V, Anton-Culver H, Esserman LJ, Madlensky L| | PubMed
  3. Breast cancer risk level and prediction of tumor aggressiveness in the Athena Breast Health Network.
    Leggat-Barr K, Lewis T, Tice JA, Tsopurashvili E, Sayaman R, Warner P, Malvin K, Sabacan L, Perry-Solomon A, Theiner S, Acerbi I, Griffin A, McGuire J, Lee V, Borowsky AD, Wisdom Study and Athena Breast Health Network Investigators and Advocate Partners, Eklund M, Kaplan C, Hiatt RA, Fiscalini AS, Kerlikowske K, Shieh Y, Esserman L, Van't Veer L| | PubMed
  4. Systematic annotation of orphan RNAs reveals blood-accessible molecular barcodes of cancer identity and cancer-emergent oncogenic drivers.
    Wang J, Suh JM, Woo BJ, Navickas A, Garcia K, Yin K, Fish L, Cavazos T, Hänisch B, Markett D, Hirst GL, Brown-Swigart L, Esserman LJ, van 't Veer LJ, Goodarzi H| | PubMed
  5. RISE UP for breast cancer 2024: conference highlights & takeaways.
    Glatt T, Leggat-Barr K, Seth N, Heditsian D, van 't Veer L, Pusztai L, Price E, Hylton N, Formenti S, Rugo H, Fejerman L, Toriola AT, Fabian C, De Censi A, Grossman D, Olopade O, Jackson A, Horton S, Rhoads K, Lange C, Borges V, Garner E, Garber J, Yee D, Esserman L| | PubMed
  6. Immune and Growth Factor Signaling Pathways Are Associated with Pathologic Complete Response to an Anti-Type I Insulin-like Growth Factor Receptor Regimen in Patients with Breast Cancer.
    Petricoin EF, Wolf DM, Yau C, Wulfkuhle JD, Van't Veer L, Gallagher RI, Esserman LJ, Hirst GL, Brown-Swigart L, Yee D, I-SPY2 Trial Consortium| | PubMed
  7. Reply to: Germline and Somatic BRCA1/2 Mutations in Breast Cancer Treatment Strategies.
    Hahnen E, Hauke J, Gelmon K, Marmé F, Ernst C, Martin M, Untch M, Bonnefoi H, Knudsen E, Im SA, DeMichele A, Van't Veer L, Kim SB, Bear H, McCarthy N, Rhiem K, Turner N, Witkiewicz A, Rojo F, Filipits M, Martin LA, Fasching PA, Schem C, Becker K, García-Sáenz JA, Kelly CM, Reimer T, Toi M, Rugo HS, Denkert C, Gnant M, Makris A, Liu Y, Valota O, Felder B, Weber K, Nekljudova V, Loibl S| | PubMed
  8. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    Van Hassel J, Dimitroff K, Yau C, Mukhtar R, Boughey JC, Ladores V, Howard-McNatt MM, Jaskowiak N, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Veer LV, Rugo H, Esserman LJ, Shatsky R, Isaacs C, Kuerer H, Wallace AM, Prionas N, Tseng J, Reyna CR, Taunk N, Kesmodel S, Lee MC, Fox J, Piltin MA, Tchou J, Arciero CA, Postlewait LM, Sauder C, Rao R| | PubMed
  9. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    Mukhtar RA, Dimitroff K, Yau C, Chien AJ, Connolly EP, Howard-McNatt M, Rao R, Ladores V, Golshan M, Sauder CA, Ahmed K, Lancaster R, Fox J, Gutnik L, Lee MC, Tchou J, Prionas N, Arciero CA, Reyna C, Kuerer H, Switalla K, Taunk N, Tuttle TM, Moran MS, Postlewait LM, Perlmutter J, DeMichele A, Yee D, Hylton N, Symmans WF, Rugo HS, Shatsky R, Isaacs C, Esserman LJ, Van't Veer L, Boughey JC| | PubMed
  10. Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication model.
    Engelhardt EG, Binuya MAE, Pharoah PDP, Poncet C, Rutgers EJT, Piccart M, Cardoso F, van 't Veer LJ, Steyerberg EW, Linn SC, Schmidt MK| | PubMed